Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2025-01-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2024-0739.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850273793943011328 |
|---|---|
| author | Naoshi Nishida |
| author_facet | Naoshi Nishida |
| author_sort | Naoshi Nishida |
| collection | DOAJ |
| format | Article |
| id | doaj-art-4562be5880f4442f8e3a50cdf0ceb87f |
| institution | OA Journals |
| issn | 2287-2728 2287-285X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj-art-4562be5880f4442f8e3a50cdf0ceb87f2025-08-20T01:51:21ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2025-01-0131131131510.3350/cmh.2024.07392031Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”Naoshi Nishida0 Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japanhttp://e-cmh.org/upload/pdf/cmh-2024-0739.pdfhepatocellular carcinomaimmune checkpoint inhibitorstumor microenvironmentbiomarkerpersonalized medicine |
| spellingShingle | Naoshi Nishida Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” Clinical and Molecular Hepatology hepatocellular carcinoma immune checkpoint inhibitors tumor microenvironment biomarker personalized medicine |
| title | Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_full | Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_fullStr | Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_full_unstemmed | Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_short | Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial” |
| title_sort | personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors editorial on genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma insights from the imbrave150 trial |
| topic | hepatocellular carcinoma immune checkpoint inhibitors tumor microenvironment biomarker personalized medicine |
| url | http://e-cmh.org/upload/pdf/cmh-2024-0739.pdf |
| work_keys_str_mv | AT naoshinishida personalizedapproachestothetreatmentofhepatocellularcarcinomausingimmunecheckpointinhibitorseditorialongenomicbiomarkerstopredictresponsetoatezolizumabplusbevacizumabimmunotherapyinhepatocellularcarcinomainsightsfromtheimbrave150trial |